Puneet Souda
Stock Analyst at Leerink Partners
(1.98)
# 3,130
Out of 5,140 analysts
219
Total ratings
48.88%
Success rate
-0.62%
Average return
Main Sectors:
Stocks Rated by Puneet Souda
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GH Guardant Health | Maintains: Outperform | $115 → $155 | $114.87 | +34.94% | 7 | Dec 15, 2025 | |
| TMO Thermo Fisher Scientific | Maintains: Outperform | $545 → $580 | $619.01 | -6.30% | 20 | Oct 22, 2025 | |
| HOLX Hologic | Maintains: Market Perform | $70 → $78 | $75.11 | +3.85% | 8 | Oct 21, 2025 | |
| CYRX Cryoport | Upgrades: Outperform | $16 | $10.75 | +48.84% | 7 | Aug 6, 2025 | |
| MASS 908 Devices | Upgrades: Outperform | $12 | $6.52 | +84.05% | 7 | Aug 5, 2025 | |
| QTRX Quanterix | Downgrades: Market Perform | $12 → $8 | $7.02 | +13.96% | 12 | Apr 30, 2025 | |
| NEO NeoGenomics | Downgrades: Market Perform | $25 → $9 | $12.64 | -28.80% | 10 | Apr 30, 2025 | |
| MYGN Myriad Genetics | Downgrades: Market Perform | $30 → $21 | $5.68 | +269.72% | 7 | Dec 9, 2024 | |
| VCYT Veracyte | Maintains: Outperform | $35 → $40 | $41.69 | -4.05% | 14 | Oct 17, 2024 | |
| NTRA Natera | Maintains: Outperform | $140 → $150 | $234.85 | -36.13% | 7 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $325 → $375 | $383.86 | -2.31% | 15 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $35 | $40.86 | -14.34% | 11 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $170 → $145 | $135.83 | +6.75% | 19 | May 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $300 | $234.33 | +28.02% | 1 | May 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $249 → $250 | $147.17 | +69.87% | 19 | Feb 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $125 → $110 | $69.57 | +58.13% | 6 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $75 | $102.35 | -26.72% | 16 | Jan 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $230 → $200 | $163.33 | +22.45% | 7 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $18 | $4.16 | +332.69% | 6 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $6 | $1.91 | +214.96% | 1 | Nov 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $45 → $30 | $41.65 | -27.97% | 6 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $85 → $87 | $49.84 | +74.56% | 13 | May 5, 2022 |
Guardant Health
Dec 15, 2025
Maintains: Outperform
Price Target: $115 → $155
Current: $114.87
Upside: +34.94%
Thermo Fisher Scientific
Oct 22, 2025
Maintains: Outperform
Price Target: $545 → $580
Current: $619.01
Upside: -6.30%
Hologic
Oct 21, 2025
Maintains: Market Perform
Price Target: $70 → $78
Current: $75.11
Upside: +3.85%
Cryoport
Aug 6, 2025
Upgrades: Outperform
Price Target: $16
Current: $10.75
Upside: +48.84%
908 Devices
Aug 5, 2025
Upgrades: Outperform
Price Target: $12
Current: $6.52
Upside: +84.05%
Quanterix
Apr 30, 2025
Downgrades: Market Perform
Price Target: $12 → $8
Current: $7.02
Upside: +13.96%
NeoGenomics
Apr 30, 2025
Downgrades: Market Perform
Price Target: $25 → $9
Current: $12.64
Upside: -28.80%
Myriad Genetics
Dec 9, 2024
Downgrades: Market Perform
Price Target: $30 → $21
Current: $5.68
Upside: +269.72%
Veracyte
Oct 17, 2024
Maintains: Outperform
Price Target: $35 → $40
Current: $41.69
Upside: -4.05%
Natera
Oct 17, 2024
Maintains: Outperform
Price Target: $140 → $150
Current: $234.85
Upside: -36.13%
Aug 1, 2024
Upgrades: Outperform
Price Target: $325 → $375
Current: $383.86
Upside: -2.31%
Jun 5, 2023
Maintains: Outperform
Price Target: $50 → $35
Current: $40.86
Upside: -14.34%
May 24, 2023
Maintains: Outperform
Price Target: $170 → $145
Current: $135.83
Upside: +6.75%
May 1, 2023
Initiates: Outperform
Price Target: $300
Current: $234.33
Upside: +28.02%
Feb 8, 2023
Maintains: Outperform
Price Target: $249 → $250
Current: $147.17
Upside: +69.87%
Feb 3, 2023
Maintains: Outperform
Price Target: $125 → $110
Current: $69.57
Upside: +58.13%
Jan 12, 2023
Maintains: Outperform
Price Target: $70 → $75
Current: $102.35
Upside: -26.72%
Jan 6, 2023
Maintains: Outperform
Price Target: $230 → $200
Current: $163.33
Upside: +22.45%
Jan 6, 2023
Maintains: Outperform
Price Target: $20 → $18
Current: $4.16
Upside: +332.69%
Nov 29, 2022
Initiates: Outperform
Price Target: $6
Current: $1.91
Upside: +214.96%
Nov 21, 2022
Maintains: Market Perform
Price Target: $45 → $30
Current: $41.65
Upside: -27.97%
May 5, 2022
Maintains: Outperform
Price Target: $85 → $87
Current: $49.84
Upside: +74.56%